Literature DB >> 1708928

Histiocytosis X arising in Hodgkin's disease: immunophenotypic characterization with a panel of monoclonal antibodies.

A Coli1, G Bigotti, S Ferrone.   

Abstract

This report describes the antigenic profile of the proliferating cells of pulmonary histiocytosis X (HX) in a patient treated with chemotherapy for Hodgkin's lymphoma; the association of pulmonary HX and Hodgkin's disease has rarely been described in the literature. The histopathological diagnosis of HX was confirmed with the aid of monoclonal antibodies (mAbs) to CD4, CD1a, and polyclonal serum anti S-100 protein. The phenotype of HX cells has been analysed using a panel of mAbs against HLA class I A, B, C monomorphic determinants, locus A and B, beta 2-microglobulin, HLA class II distinct monomorphic determinants, DP, DQ, DR, intercellular adhesion molecule-1 (ICAM-1) and vitronectin receptors. Our results indicate that HX cells express HLA class I and II, including locus A, locus B and DP, DQ, DR, like their normal counterpart (represented by Langerhans cells) and detectable levels of ICAM-1 but not vitronectin receptors. We would like to stress the possibility of the association of HX and Hodgkin's lymphoma extending the immunophenotypic profile of HX cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1708928     DOI: 10.1007/bf01600168

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  24 in total

Review 1.  Integrins: a family of cell surface receptors.

Authors:  R O Hynes
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

2.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

3.  Langerhans' cell granulomatosis (histiocytosis X) associated with malignant lymphomas.

Authors:  B F Burns; T V Colby; R F Dorfman
Journal:  Am J Surg Pathol       Date:  1983-09       Impact factor: 6.394

4.  Selective changes in expression of HLA class I polymorphic determinants in human solid tumors.

Authors:  P G Natali; M R Nicotra; A Bigotti; I Venturo; L Marcenaro; P Giacomini; C Russo
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

5.  Adhesion molecules on the plasma membrane of epidermal cells. I. Human resting Langerhans cells express two members of the adherence-promoting CD11/CD18 family, namely, H-Mac-1 (CD11b/CD18) and gp 150,95 (CD11c/CD18).

Authors:  G De Panfilis; D Soligo; G C Manara; C Ferrari; C Torresani
Journal:  J Invest Dermatol       Date:  1989-07       Impact factor: 8.551

6.  Phenotypic transformation of macrophages to Langerhans cells in the skin.

Authors:  G F Murphy; D Messadi; E Fonferko; W W Hancock
Journal:  Am J Pathol       Date:  1986-06       Impact factor: 4.307

7.  Pulmonary Langerhans' cells in patients with fibrotic lung disorders.

Authors:  O Kawanami; F Basset; V J Ferrans; P Soler; R G Crystal
Journal:  Lab Invest       Date:  1981-03       Impact factor: 5.662

8.  S-100 staining in the diagnosis of eosinophilic granuloma of lung.

Authors:  D Webber; V Tron; F Askin; A Churg
Journal:  Am J Clin Pathol       Date:  1985-10       Impact factor: 2.493

9.  Immunocytochemical characterization of pulmonary histiocytosis X cells in lung biopsies.

Authors:  P Soler; S Chollet; C Jacque; Y Fukuda; V J Ferrans; F Basset
Journal:  Am J Pathol       Date:  1985-03       Impact factor: 4.307

10.  Antigenic phenotype of Langerhans cell histiocytosis: an immunohistochemical study demonstrating the value of LN-2, LN-3, and vimentin.

Authors:  N Azumi; K Sheibani; W G Swartz; R M Stroup; H Rappaport
Journal:  Hum Pathol       Date:  1988-12       Impact factor: 3.466

View more
  1 in total

Review 1.  Pulmonary langerhans cell histiocytosis.

Authors:  Harpreet S Suri; Eunhee S Yi; Gregorz S Nowakowski; Robert Vassallo
Journal:  Orphanet J Rare Dis       Date:  2012-03-19       Impact factor: 4.123

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.